“South Africa begins the rollout of lenacapavir, a long-acting HIV prevention injection, across Gauteng clinics. While hailed as a breakthrough, limited access raises equity concerns.”
The introduction of lenacapavir in Gauteng marks a milestone in South Africa’s fight against HIV. Unlike daily oral PrEP, lenacapavir requires only biannual injections, significantly reducing adherence challenges. Clinics report strong uptake among key populations, including sex workers and young women, who face disproportionate HIV risk. Yet, critics argue that limiting rollout to Gauteng creates inequities, leaving rural provinces behind. Health activists stress that HIV prevention must be universal, not selective. The Department of Health acknowledges logistical challenges, citing cold-chain requirements and training gaps. International donors have praised South Africa’s leadership, but warn that sustainability depends on local manufacturing and funding. Patients interviewed describe relief at not needing daily pills, but also frustration at long queues and limited clinic staff. Experts highlight that lenacapavir is not a cure, but a prevention tool that must be integrated with education, testing, and treatment. The rollout illustrates both progress and persistent barriers in South Africa’s HIV response, underscoring the need for nationwide expansion.
